Immuneering
IMRX | NASDAQ
$3.52
-$0.19 (-5.12%)
At close: Nov 16, 2026, 4:00 PM ET
$3.52
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:34 PM ET
-5.12%
(1D)No price chart data available for 1D timeframe.
Rating
35
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #657/1021 (Top 64%)
Key Statistics
Market Data
Market Cap $227.97M
1D Range
3.48 3.76
52W Range
3.37 8.33
Valuation (TTM)
PE -3.42
PB 1.35
EV/EBITDA -1.19
Valuation (NTM)
Forward PE N/A
Forward PEG 0.32
Price Target $14.00
Cash Flow
FCF Yield -22745.7%
SBC Adj. FCF Yield -25082.5%
SBC Impact -10.3%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
-100.0%
Dil EPS 3Y | 5Y 29.5% |
9.7%
FCF 3Y | 5Y -149.6% |
-99.5%
Returns
ROA -36.4%
ROE -33.9%
ROIC -42.9%
Financial Health
Net Cash
$141.87M
Current Ratio 13.97
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development effort...
Sector Healthcare
Industry Biotechnology
Employees 57
IPO Date Jul 30, 2021
Website immuneering.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
2
Consensus
Buy
Price Target
$14.00
Upside
+297.73%
Buy (2)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove IMRX